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Abstract
Background Respiratory insufficiency occurs in 20 % of
Guillain–Barre´ syndrome (GBS) patients, and the duration
of mechanical ventilation (MV) ranges widely. We iden-
tified predictors of prolonged MV to guide clinical
decision-making on tracheostomy.
Methods We analyzed prospectively collected data from
552 patients with GBS in the context of two clinical trials
and three cohort studies in The Netherlands. Potential
predictors for prolonged MV, defined as duration of
C14 days, were considered using crosstabs. Selected pre-
dictors were analyzed using Cox regression analysis.
Results On a total of 150 (27 %) patients requiring MV,
106 (71 %) patients needed prolonged MV. The median
duration of MV was 28 days (Interquartile Range [IQR]
12–60 days). The strongest observed predictors of pro-
longed MV were muscle weakness and axonal
degeneration or unexcitable nerves on nerve conduction
studies. Patients who are unable to lift the arms from the
bed (bilateral Medical Research Council [MRC] of deltoid
muscles of 0–2) at 1 week after intubation have an 87 %
chance to require prolonged MV versus 69 % in patients
who are able to lift the arms from the bed (bilateral MRC
of deltoid muscles of 3–10). Patients in this last group who
had axonal degeneration or unexcitable nerves on nerve
conduction studies also have a 90 % chance to require
prolonged MV.
Conclusions Ventilated GBS patients who are unable to
lift the arms from the bed and patients who have axonal
degeneration or unexcitable nerves at 1 week are at high
risk of prolonged MV, and tracheostomy should be con-
sidered in these patients.
Keywords Guillain–Barre´ syndrome 
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Introduction
Respiratory failure is a life-threatening manifestation of the
Guillain–Barre´ syndrome (GBS) that occurs in 20–30 % of
patients with GBS [1–4]. Immunomodulatory treatment
reduces the proportion of patients who require mechanical
ventilation (MV) as well as the duration of MV [5, 6]. The
duration of the required MV varies widely in GBS, ranging
from a few days to several months and even longer than
1 year. In general, tracheostomy should be considered
when the expected ventilation duration is more than
14 days [7, 8]. The uncertainty about the duration of
required MV in individual patients may complicate this
decision in clinical practice. Delayed tracheostomy in
ventilated patients may result in avoidable damage of the
vocal cords, laryngeal mucosa, and recurrent laryngeal
nerves due to decubitus or local pressure from the endo-
tracheal tube [7]. On the other hand, early tracheostomy
may be unnecessary because of clinical improvement and
exposes patients to the risk of perioperative bleeding,
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infection, esophageal perforation, pneumothorax, and tra-
cheal stenosis and, in all cases, leaves a permanent scar [9].
Previous studies showed that the clinical course of GBS
in individual patients can be predicted with reasonable
accuracy [10–14]. In the current study, we described the
variability in duration of MV and characteristics of GBS
patients with prolonged MV and aimed to identify pre-
dictors of prolonged MV. These predictors may support
individual clinical decision-making about indication and
timing of tracheostomy in patients with GBS early in the
course of their disease.
Patients and Methods
Patients
Prospectively collected data were used from 552 patients
who fulfilled the diagnostic criteria for GBS, were treated
with either plasma exchange or intravenous immunoglob-
ulins, and did not die in the first week of hospital
admission. These patients previously participated in a
treatment trial [15, 16], an observational study [17], or a
pilot study [18, 19] conducted by the Dutch GBS Study
Group. The ethical review board of Erasmus MC approved
all studies, and all patients gave written informed consent
to use their data for further research.
Data Collection
Data collected prospectively for all patients were age, gen-
der, preceding infections, number of days from onset of
weakness to hospital admission, date of intubation and
extubation, and neurological examination (cranial nerve
testing, sensory and motor testing; using the Medical
Research Council [MRC] sumscore) at predefined time
points (at admission and at 3, 7, 14, 28, 90, and 181 days after
admission). The MRC sumscore is defined as the sum of
MRC scores of six different muscles measured bilaterally,
which results in a sumscore ranging from0 (tetraplegic) to 60
(normal). For this study, we recorded neurological exami-
nation at 1 week after intubation. Nerve conduction studies
were performed in the first 2 weeks after inclusion, and the
data were used to classify GBS as acute inflammatory
demyelinating polyradiculoneuropathy (AIDP), acute motor
axonal neuropathy (AMAN), equivocal, or unresponsive
according to the Hadden criteria [20]. Serological screening
was performed to determine recent infections with Campy-
lobacter jejuni, cytomegalovirus, Epstein–Barr virus, and
Mycoplasma pneumonia and antibodies to the gangliosides
GM1, GD1a, and GQ1b. The serum samples used were
obtained within 4 weeks from onset of weakness and before
start of treatment and were stored at -80 C until use.
Endpoints
The primary endpoint in our study is the occurrence of
prolonged MV, defined as MV of more than 14 days, as an
established criterion to consider tracheostomy [7, 8]. In
addition, we determined the risk of requiring MV for more
than 21 and 28 days. We defined liberation from MV as
either successful extubation or spontaneous breathing off
the ventilator in tracheotomized patients for more than
24 h. Predictors of prolonged MV were sought at day 7
after start of ventilation, as a clinical decision point for
considering early tracheostomy. Also, we determined the
time to reach the ability to walk unaided in different patient
groups.
Statistical Analysis
A Kaplan–Meier curve with log-rank test was used to
compare time to reach the ability to walk unaided during a
follow-up period of 6 months between patients with pro-
longed MV, patients with MV for <14 days, and patients
not requiring MV. Potential predictors for prolonged MV
were considered in crosstabs, and univariate logistic
regression models and odds ratios (ORs) indicated relative
effects of predictors. Cox regression analysis was used to
further analyze selected predictors and calculate the esti-
mated risk percentages for prolonged MV duration (C14,
C21, and C28 days). A Cox regression model was used
since our cohort was relatively small. Using specific cut-
offs of long versus short MV duration would result in low
numbers of patients in specific categories and unsta-
ble models. Cox regression accounts for the total duration
of ventilation and thus uses the data more efficient than
logistic regression with a binary outcome (long vs. short
MV). Missing values were imputed based on relevant
covariates and outcome. A two-sided p value <0.05 was
considered to be statistically significant. Statistical analyses
were conducted with SPSS for Windows and R statistical
software (version 2.7, using the design library).
Results
Mechanical Ventilation in GBS
In the cohort of 552 patients with GBS, 150 (27 %)
required MV at some time during the follow-up of
6 months. The median duration of the MV was 28 days
(Interquartile Range IQR 12–60 days; absolute range 1 to
>81 days; Fig. 1). Patients were intubated at a median of
1 day after admission (IQR 0–4). The timing of intubation
was not correlated with the MV duration (Table 1). Eight
patients in the MV group (5 %) died during the follow-up
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period of 6 months. Mortality was not significantly dif-
ferent between the patients who needed prolonged MV
(6 %) and those who did not (5 %). The indication for
intubation was not systematically documented, but the
percentage of bulbar weakness was not significantly dif-
ferent between the two groups.
MV was associated with poor outcome, as 57 % in the
ventilated group regained the ability to walk in the first
6 months, in comparison with 87 % in the unventilated
group (OR 5.0 [3.2–7.7], p < 0.001). Patients with pro-
longed MV also needed more time to regain the ability to
walk than the patients with MV <14 days (log-rank test,
p < 0.001) (Fig. 2). Forty-four patients who required MV
<14 days had a comparable recovery as the 402 unventi-
lated patients (log-rank test, p = 0.2) (Fig. 2).
Prediction of MV Duration
Predictors of prolonged MV were determined at day 7 after
start of ventilation, which was considered a critical time
point in clinical practice to make a decision about tra-
cheostomy. Patients requiring MV for 7 days or less
(N = 18) were excluded from this analysis (Fig. 3). In the
remaining 132 patients, 106 (80 %) needed prolonged MV
(Fig. 3). In Table 1, the observed frequencies of potential
predictors and crude associations with prolonged MV are
shown. The strongest predictor of prolonged MV was
severe limb weakness defined by the MRC sumscore
1 week after intubation (p < 0.001; Table 1). Further
analysis showed that the MRC scores of the bilateral del-
toid muscles alone also were a strong predictor of
prolonged ventilation (p < 0.001; Table 1). Furthermore,
a total of 61 patients were unable to lift the upper arms
(bilateral MRC score B2), and 58 (95 %) of those needed
prolonged MV (OR 9.3 [2.6–32.7], p = 0.001; Table 1).
Also, regression (OR 3.7, 95 % CI, 0.4–3.0) or improve-
ment (OR 0.2, 95 % CI, 0.06–0.7) of muscle strength of the
bilateral deltoid muscles was predictive of prolonged
ventilation (p = 0.007). Patients with AMAN (N = 4) or
unexcitable nerves (N = 15) all required prolonged MV
(Table 1); and therefore, it was not possible to calculate an
OR or p value in univariate analysis. Because of the small
patient numbers in the nerve conduction study (NCS)
subgroups, we divided the patients for the multivariate
analysis into two groups: AMAN or unexcitable versus
AIDP or equivocal. In addition, all patients with serum
anti-GQ1b antibodies (N = 10) required MV. We used
Cox regression analysis to predict chances to require MV
for more than 14, 21, and 28 days in the different groups
based on the condition of the patient after 1 week of
mechanical ventilation (Table 2). Based on this model,
patients who were unable to lift the arms from the bed had
an estimated chance of prolonged MV for more than
14 days of 87 % (Table 2). NCS results significantly con-
tribute to the prediction and can be taken into
consideration.
Fig. 1 Duration of mechanical
ventilation in 149 patients with
GBS. The figure indicates the
duration of mechanical
ventilation in 149 patients with
Guillain–Barre´ syndrome. One
patient of the original cohort of
150 ventilated patients was
excluded because the patient
was lost to follow-up after
3 months of ventilation. Median
duration of mechanical
ventilation was 28 days,
interquartile range of
12–60 days, absolute range 1 to
>181 days (follow-up of the
studies ended at 181 days)
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Table 1 Characteristics of the cohort of 132 Guillain–Barre´ syndrome patients on the ventilator for at least 7 days in relation to prolonged
mechanical ventilation
Characteristic Total N (%) prolonged MV
(C14 days)
Median (IQR) days on
ventilator
OR (95 % CI) for
prolonged MV
p value
Total 132 106 (80 %) 31 (16–63)
Demographic features
Age (in years) NS
B40 41 32 (78 %) 23 (16–57) Ref
41–60 41 34 (83 %) 40 (21–77) 1.4 (0.5–4.1)
>60 50 40 (80 %) 30 (16–60) 1.1 (0.4–3.1)
Gender (male) 71 57 (80 %) 30 (16–63) 1.0 (0.4–2.4) NS
Clinical severitya
Days from onset weakness to MV 1.0 (0.9–1.0) NS
Bulbar weakness 28 22 (79 %) 52 (15–78) 0.9 (0.3–2.4) NS
Facial weakness 56 46 (82 %) 41 (17–67) 1.2 (0.5–3.0) NS
MRC sumscore <0.001
41–60 18 7 (39 %) 11 (8–20) 0.2 (0.04–0.5)
21–40 43 35 (81 %) 28 (15–44) Ref
0–20 71 64 (90 %) 49 (25–80) 2.1 (0.7–6.3)
M. deltoideusb 0.7 (0.6–0.8) <0.001
M. deltoideus dichotomized 0.001
MRC 0–2 61 58 (95 %) 53 (27–82) 9.3 (2.6–32.7)
MRC 3–10 71 48 (68 %) 21 (12–40) ref
M. bicepsb 0.7 (0.6–0.9) <0.001
M. extensor carpi radialisb 0.8 (0.6–0.9) 0.001
M. iliopsoasb 0.7 (0.6–0.9) <0.001
M. quadricepsb 0.7 (0.6–0.9) <0.001
M. tibialis anteriorb 0.8 (0.7–0.9) 0.002
Nerve conduction studies
AIDP 64 48 (75 %) 29 (14–54) Q Q
AMAN 4 4 (100 %) 131 (69–178)
Equivocal 26 20 (77 %) 23 (15–49)
Unexcitable 15 15 (100 %) 82 (62–171)
Infection and serology
Symptoms of preceding infectionc
Diarrhea 32 27 (84 %) 45 (21–112) 1.44 (0.5–4.2) NS
Upper respiratory tract infection 47 33 (70 %) 24 (13–66) 0.4 (0.2–0.9) 0.03
Infection serologyd
Campylobacter jejuni 43 37 (86 %) 44 (20–87) 1.8 (0.7–5.0) NS
Cytomegalovirus 20 18 (90 %) 52 (26–63) 2.7 (0.6–12.6) NS
Epstein–Barr virus 13 12 (92 %) 29 (23–73) 3.5 (0.4–28.1) NS
Mycoplasma pneumonia 6 5 (83 %) 20 (17–26) 1.3 (0.2–11.8) NS
Anti-ganglioside IgM/IgG antibodies
GM1 14 12 (86 %) 91 (18–176) 1.6 (0.3–7.6) NS
GD1a 9 8 (89 %) 23 (16–60) 2.2 (0.3–18.4) NS
GQ1b 10 10 (100 %) 49 (16–60) Q Q
MV mechanical ventilation, IQR interquartile range, OR odds ratio, CI confidence interval, MRC Medical Research Council, AIDP acute
inflammatory demyelinating polyradiculoneuropathy, AMAN acute motor axonal neuropathy. Q Because of 100 % values, it was impossible to
calculate ORs and p values for AMAN, unexcitable nerves, and anti-GQ1b antibodies
a At 1 week after intubation
b Sum of MRC grades for bilateral muscle groups
c Symptoms of infection in the 4 weeks preceding the onset of weakness
d Using pretreatment serum samples obtained at entry
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Discussion
The decision for tracheostomy in patients with GBS
depends on the expected duration of respiratory failure,
which may range from a few days to more than 6 months.
In the current study, MV was required in 27 % of patients
and 71 % of these patients required MV for more than
14 days. Eighty percent of the patients who were still
intubated after 1 week required prolonged MV. The chance
of prolonged MV was further increased in the subgroup of
patients with severe paresis of the deltoid muscles, defined
as being unable to lift the arms from the bed (MRC grade 0
or 1 bilaterally), and the patients with an axonal or unre-
sponsive polyneuropathy in the NCS. In these patients, it
may be considered to perform an early tracheostomy.
Our study confirms previous findings by others that the
duration of MV in GBS is associated with the extent of
limb muscle weakness. Fourrier et al. [14] reported that the
lack of foot flexion at the end of immunotherapy was a
predictor for prolonged MV in a group of 40 ventilated
GBS patients in a retrospective, single-center study. They
did not report on the predictive value of paresis of other
limb muscles. In the current study, we confirmed the
association between prolonged MV and paresis of the
anterior tibial muscle; but stronger associations were found
for paresis of the deltoid, biceps, iliopsoas, and quadriceps
muscles. These results provide further support for the
hypothesis that patients with prolonged MV have a severe
diffuse neuropathy, which affects both the respiratory and
limb muscles. We preferred to use the deltoid muscle for
the prognostic model because of the strong association with
prolonged MV, its common C5 innervation with the
phrenic nerve, and relatively easy accessibility for physical
examination in bed-bound patients. However, when the
examination of the deltoid muscles is not possible in an
individual patient, substitution of other preferably proximal
muscle groups, such as the iliopsoas muscles, seems
plausible.
In the current study, all ventilated patients with AMAN
(N = 4) and unexcitable nerves (N = 15) required pro-
longed MV. This finding is in line with previous findings
[1, 21]. One study indicated that the presence of AIDP was
associated with a higher chance of respiratory failure [22],
but we were unable to confirm that finding. The electro-
physiology results are influenced by the applied
classification criteria and the timing of the NCS. In Wes-
tern countries, the axonal forms of GBS are relatively rare
compared to AIDP and are found in 5–10 % of GBS
patients. In addition, NCS performed at 1 week is less
accurate for identifying axonal GBS, as the axonal pattern
may appear only after 2–4 weeks. At 1 week of admission,
patients more frequently show unexcitable nerves in NCS.
These patients may have either AIDP or axonal forms, but
in all cases this is a sign of severe diffuse neuropathy. As
such, unexcitable nerves may be a more frequent indication
than AMAN for early tracheostomy.
Remarkably, our study showed that all 10 ventilated
patients with serum anti-GQ1b antibodies required pro-
longed MV. Antibodies to GQ1b in patients with GBS are
strongly associated with the occurrence of ophthalmoplegia
and swallowing disorders. Some studies indicated that
these patients are prone to develop respiratory failure [23],
but this was not found by others [11, 24]. As far as we
know, the current study is the first to demonstrate the
relation between GQ1b antibodies and the duration of MV
Fig. 2 Outcome of GBS in relation to duration of mechanical
ventilation. Relation between mechanical ventilation, its duration, and
the time (in days) to recover to independent walking in a cohort of
552 patients with Guillain–Barre´ syndrome. Kaplan–Meier curves
show the proportion of patients who regained the ability to walk
unaided during a follow-up of 181 days
Fig. 3 Flowchart of patient subgroups in relation to mechanical
ventilation. MV mechanical ventilation, N number of patients
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in ventilated patients with GBS. Some of these patients
also had severe weakness of arms and legs or unex-
citable nerves, indicating that the presence of anti-GQ1b
antibodies is probably not an independent prognostic fac-
tor. A further limitation of this biomarker for supporting
the decision of tracheostomy in current clinical practice is
the delay and quality of the test results, which are influ-
enced by the used assay protocol. Because of these
limitations, we have not used the test in the current prog-
nostic models.
We were unable to confirm the finding from a previous
retrospective, single-center study in 60 ventilated GBS
patients that age is an independent predictor for prolonged
MV [21]. In most studies, older age is a predominant
prognostic factor for poor outcome in GBS, including those
of our own group. In the current study, we found no
association between age and prolonged MV (OR 1.1 for
age >60 years), neither did other previous studies. Also
the presence of a preceding C. jejuni infection, which is a
general poor prognostic factor in GBS, was not predictive
for prolonged MV. Previously, we showed that selective
gut decontamination may shorten the time of MV and
admission to ICU but does not shorten the time to reach the
ability to walk [25]. Apparently, the recovery from respi-
ratory failure depends on other factors than the recovery of
limb weakness.
The current study has several limitations that need to be
addressed. First, the group of ventilated patients was too
small to be able to develop and validate a prognostic
model, as was done previously for predicting respiratory
failure in the first week in GBS [11]. To overcome this
limitation in part, we used Cox regression analysis that also
takes the total duration of MV into account. This resulted
in slightly lower, but presumably more realistic, predic-
tions of MV duration. For example, we observed that all
patients with the axonal subtype or unexcitable nerves
(100 %) needed prolonged MV. Model-based prediction in
this subgroup resulted in a 93 % chance of prolonged MV
(univariate; data not shown). Hence, some predictors of
prolonged MV were present in even smaller subgroups,
such as the axonal subtype and anti-GQ1b antibodies,
although all these patients had prolonged MV. Second, the
patient population investigated was biased toward adult
patients and patients with AIDP, which is the predominant
GBS subtype in The Netherlands. The observed finding at
present cannot be extrapolated to pediatric GBS or coun-
tries where axonal forms predominate. Third, in this
multicenter study, differences in the duration of MV may
reflect variation in local clinical management; intubation or
extubation criteria were not used in our patient group. Also,
usage and timing of tracheostomy was not recorded in our
cohort, and this probably influenced the duration of MV.
All patients were included in previous trials, which have
the advantage of protocoled, repeated clinical assessments,
but could have influenced the standard clinical care.
Fourth, in the current study we have used data collected in
various previous studies conducted in the last 25 years. We
cannot exclude that the criteria for extubation and sup-
portive care have changed over time. In the future,
international prospective validation studies in larger
cohorts of GBS patients, including children and patients
from other regions and with clear definitions regarding
extubation criteria, will be needed to substantiate our
findings.
Debate is still ongoing about the optimal timing of tra-
cheostomy. A consensus report on MV indicated that the
translaryngeal route is preferred when the expected dura-
tion is not exceeding 10 days, while tracheostomy is
preferred for expected durations longer than 21 days [26].
Prolonged MV via the translaryngeal route carries signifi-
cant risks, while tracheostomy has its own complications
and leaves permanent disfigurement. Nowadays prospec-
tive trials show that early tracheostomy was associated
with less sedative and analgesic administration, less fre-
quent prescriptions of haloperidol to treat agitation or
delirium, earlier oral nutrition, and out-of-bed
Table 2 Predicted chances (Cox regression analysis) of a total mechanical ventilation duration of C14, C21, and C28 days
Condition at 1 week after intubation N Chance (%, 95 % CI) of a total MV duration of
C14 days C21 days C28 days
Mechanical ventilation (observed) 131 80 66 55
Mechanical ventilation and unable to lift arms 61 87 (81–92) 77 (70–85) 68 (60–78)
Mechanical ventilation and unable to lift arms and axonal NCS/unexcitable NCS 16 96 (93–98) 93 (87–97) 89 (82–95)
Mechanical ventilation but able to lift arms and axonal NCS/unexcitable NCS 5 90 (84–96) 83 (73–93) 75 (63–89)
Mechanical ventilation but able to lift arms and AIDP or equivocal NCS 65 67 (58–78) 48 (38–60) 34 (24–46)
AIDP acute inflammatory demyelinating polyneuropathy, CI confidence interval, MV mechanical ventilation, N number, NCS nerve conduction
study
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mobilization. Early tracheostomy does not seem to shorten
the duration of MV, length of hospital stay, mortality, or
frequency of infectious complications [8, 27–30].
Conclusion
Most GBS patients on MV after 1 week will require pro-
longed MV, and the chances are further increased in
patients with severe deltoid muscle weakness and axonal/
unexcitable NCS. These patients are candidates for early
tracheostomy.
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